This targeted strand of the Gilead Fellowship and Medical Grants Programme awards up to £50,000 for one-year projects that improve the CAR T cell therapy patient pathway in haemato-oncology. Funds support initiatives spanning shared-care models, outcomes monitoring, infrastructure development, and educational tools to optimize patient care.
Eligibility Criteria:
-
Open to healthcare and third-sector organisations based in the UK or Ireland.
-
Projects must focus on the CAR T cell therapy patient pathway and demonstrate measurable impact.
-
Applicants should be able to communicate progress and present findings at programme close.
-
Proposals outside the suggested scope—but adding clinical value or addressing unmet needs—are welcome for merit-based review.
Funding Details:
-
Amount: Up to £50,000.
-
Duration: 1 year, single-cycle grant.
-
Use of Funds: Examples include:
-
Efficiency initiatives and shared-care pathways between referring centres and CAR T treatment sites.
-
Audits of patient profiles, treatment patterns, and disease outcomes.
-
Monitoring tools for patient-reported outcomes, quality of life, or caregiver education.
-
New infrastructure/processes for diagnosis, safety monitoring, or efficacy prediction.
-
Research into detection and treatment of specific patient subgroups.
-
Deadline:
Application window opens April 4, 2025 and closes July 4, 2025.
Where to Go for Further Information:
Submit applications and access full guidelines via the Gilead Sciences UK & Ireland Grants Portal.
For enquiries, email: [email protected].